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Aim: To evaluate the role of optical coherence tomography
(OCT) in determining choroidal neovascularisation (CNV)
activity before and after photodynamic therapy (PDT) in
patients with pathological myopia.
Methods: 33 patients (33 eyes) with pathological myopia and
being treated with PDT were included. Every 3 months all
patients were evaluated and presence or absence of leakage on
fluorescein angiography, presence of intraretinal or subretinal
fluid on OCT, and macular and choroidal neovascular complex
thickness on OCT, were determined at each examination.
Results: The macular thickness decreased significantly after PDT
at 6 months (p = 0.001) and at 12 months follow up (p = 0.01).
However, no significant changes in CNV thickness were
measured after PDT at 6 months of follow up (p = 0.418) and
at 12 months of follow up (p = 0.521). Once the diagnosis of
CNV associated with pathological myopia was established,
before treatment, OCT had a sensitivity of 96.96% for detecting
CNV activity. After treatment, OCT had a good sensitivity
(95.23%) and a moderate specificity (69,69%) in determining
CNV activity, which resulted in a diagnostic efficiency
(proportion of correct results) of 79.62%.
Conclusions: OCT appears to be useful for indicating CNV
activity. Therefore, it may serve as a complementary
technique for deciding the need for PDT and re-treatment
in patients with pathological myopia.
P
athological myopia is a major cause of blindness,1 2 and
in many cases the vision loss is the result of the
development of choroidal neovascularisation (CNV).3
The results of the Verteporfin in Photodynamic (VIP)
studies4 5 showed that photodynamic therapy (PDT) is
beneficial for subfoveal CNV related to pathological myopia.
Currently, fluorescein leakage from CNV on fluorescein
angiography (FA) is the main criterion in the decision to
treat and re-treat using PDT.4 5
We recently found that OCT is useful for identifying CNV
activity and that OCT may be a complementary technique for
determining the need for PDT and re-treatment in patients
with age related macular degeneration (AMD).6
The aim of the current study was to assess the sensitivity
and specificity of OCT in detecting the presence of subretinal
or intraretinal fluid for identifying CNV activity before and
after PDT in patients with CNV associated with pathological
myopia. We also evaluated the role of OCT in detecting
changes associated with PDT in these patients.
METHODS
A total of 33 consecutive patients who presented with signs of
pathological myopia were included in this prospective
observational case study.
The research followed the tenets of the Declaration of
Helsinki; and the study was approved by the university clinic
research committee. The best corrected visual acuity (BCVA)
was evaluated using the Snellen chart by the same certified
optometrist. During disease evolution, when the BCVA
reached 20/400, ETDRS at 2 metres was used and the visual
acuity (VA) was expressed as the Snellen equivalent.
The same two independent observers determined the
presence or absence of leakage on the angiograms in each
case. When the two observers did not agree, the judgment of
the senior retina specialist was accepted as valid.
Optical coherence tomograms were obtained with a
commercially available unit (OCT3, Humphrey-Zeiss,
Dublin, CA, USA) using the previously reported methodol-
ogy.6–8 The same experienced technician performed all OCT
evaluations. Another independent observer, who was masked
to the patient status, evaluated the OCT scans on each
occasion. The following data were recorded: retinal thickness
at the fovea, CNV complex thickness, and the presence or
absence of subretinal and intraretinal fluid. Measurements of
the retinal thickness at the fovea were performed using a
manually assisted technique in the system software (version
A 1.1; Zeiss-Humphrey). Foveal fixation and landmark
functions were used to perform every scan in the same
macular region.
CNV was considered present in cases in which well defined
thickness and fragmentation of the retinal pigment epithe-
lium (RPE)/choriocapillaris reflection were observed.9 Only
the well defined CNV on the OCT scans were measured
manually to determine thickening. If subretinal or intrar-
etinal fluid was present on the OCT scan, that remark was
considered positive. FA was considered the standard refer-
ence for these two findings on OCT and was considered
positive when leakage was present.
Statistical analysis
Sensitivity, specificity, diagnostic efficiency, and the like-
lihood ratio for a positive and a negative test were calculated
for OCT, with FA as the standard reference. The Student t test
was used to assess differences between paired means
(macular and CNV thickness change). Two tailed p values
less than 0.05 were considered significant. The association
between the pretreatment macular thickness and the
pretreatment CNV thickness with BCVA evolution (post-
treatment minus pretreatment BCVA) was calculated with
Pearson’s correlation coefficient.
RESULTS
Thirty three consecutive white patients (11 men, 22 women)
were included in this study. The average age was 52.06 (SD
9.49) years.
Abbreviations: AMD, age related macular degeneration; BCVA, best
corrected visual acuity; CNV, choroidal neovascularisation; FA,
fluorescein angiography; OCT, optical coherence tomography; PDT,
photodynamic therapy; RPE, retinal pigment epithelium; VIP study,
Verteporfin in Photodynamic study
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Macular thickness was measured using OCT at the
pretreatment examination and at the 6 month follow up
visit in these 33 eyes. At the 12 month follow up examina-
tion, the macular thickness was measured in 29 eyes. The
mean number of treatments in the group followed for
12 months (n = 29) was 2.06 (SD 1.24, range 1–5). Table 1
shows the data regarding macular thickness and CNV
thickness. A statistically significant difference was observed
between the macular thickness at 6 months and the
pretreatment macular thickness (paired t test; p = 0.001). A
significant difference also was found between the macular
thickness at the 12 month follow up visit and the pretreat-
ment macular thickness (paired t test, p = 0.01).
The thickness of the CNV complex also was obtained at the
same examinations. At pretreatment a well defined CNV on
the OCT scans was identified and measured in 24 of 33 eyes
(72.72%). At the 6 month follow up visits, in the same 24 of
33 eyes, the CNV complex was again identified. At the 12
month follow up visit, well defined CNV on the OCT scans
was measured in 20 of 29 eyes (68.96%). In the rest of the
scans, the CNV could not be clearly identified clearly. No
statistically significant change in CNV thickness was
observed at the 6 month follow up examination compared
with the pretreatment CNV thickness (paired t test,
p = 0.418) (table 1). Likewise, the difference between the
CNV thickness at the 12 month follow up visit and
pretreatment was not statistically significant (paired t test,
p = 0.521).
No significant correlation was found between the pretreat-
ment macular thickness and changes in the BCVA after
6 months (r = 0.167; p = 0.368) or 12 months (r = 0.024;
p = 0.907). Likewise, no significant correlation was found
between the pretreatment CNV thickness and changes in
BCVA after 6 months (r = 0.091; p = 0.672) or 12 months
(r = 0.288; p = 0.218).
There was agreement on the presence of leakage between
the two observers in 119 of 141 angiograms interpreted.
Before treatment, FA leakage was seen in all eyes, and OCT
detected the presence of either intraretinal or subretinal fluid
(fig 1) in 32 of 33 eyes (96.96%). Therefore, with FA as the
reference standard, OCT had a sensitivity of nearly 97% in
detecting CNV activity. Only one case (3.03%) in which
leakage was present on pretreatment FA was considered
negative on OCT.
After treatment leakage was observed on 42 angiograms; in
40 (95.23%) of them OCT showed intraretinal or subretinal
fluid (fig 2). Nevertheless, of a total of 66 angiograms in
which no leakage was observed, only 46 (69.69%) had no
intraretinal or subretinal fluid (fig 3). With FA as the
standard, OCT achieved a sensitivity of 95.23% in determin-
ing CNV activity after treatment. However, OCT obtained a
moderate specificity of 69.69%. The likelihood ratio for a
Table 1 Change in macular and choroidal neovascularisation (CNV) thickness after
photodynamic therapy
Pretreatment 6 Months 12 Months
Retinal thickness at fovea (SD) (mm) 363 (102)
(n = 33)
310 (93)
(n = 33)
310 (96)
(n = 29)
CNV thickness (SD) (mm) 175 (43)
(n = 24)
168 (39)
(n = 24)
170 (50)
(n = 20)
Statistically significant difference with respect to the pretreatment measure (p = 0.001); statistically significant
difference with respect to the pretreatment measure (p = 0.01).
Figure 1 Pretreatment of the right eye
of a patient with pathological myopia.
Top left, fundus photograph shows
characteristic of pathological myopia
and signs of choroidal
neovascularisation (CNV). Top right,
optical coherence tomography (OCT)
shows subretinal fluid (asterisk). The
CNV complex also is identifiable in
OCT scan (white arrow). Bottom left,
early phase of angiogram shows a
classic CNV membrane. Bottom right,
leakage on a late phase angiogram.
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positive test was 3.06, and the likelihood ratio for a negative
test was 0.07. OCT had a diagnostic efficiency of 79.62% to
detect post-treatment CNV activity in the presence of
intraretinal or subretinal fluid.
DISCUSSION
In the present study, we demonstrated that when CNV
secondary to pathological myopia was diagnosed with
intraretinal and subretinal fluid, OCT seemed to have
excellent sensitivity and moderate specificity in detecting
CNV activity, with FA leakage as the standard test.
Our results indicated that the macular thickness decreased
significantly at the 6 month and 12 month examinations. We
hypothesise that the reduction in macular thickness in our
series of eyes resulted from partial or total resolution of the
subretinal fluid, intraretinal fluid, or both.10
We identified the CNV complex in 72.72% of eyes at
pretreatment. These percentages are only slightly higher that
those we obtained in a series of eyes with predominantly
classic CNV secondary to ARMD.6 Hee et al9 described that the
CNV complex was better defined by OCT in classic lesions.
Because most of the CNV lesions in pathological myopia are
only classic and located above the RPE, it was easier to detect
the suspected CNV complex by OCT. However, because OCT
cannot differentiate blood from fibrosis on CNV, OCT alone
cannot be used to detect CNV. Currently, posterior pole
Figure 2 The right eye of a patient
3 months after the second
photodynamic therapy sesion. Top left,
fundus photograph shows
ophthalmoscopic signs of CNV,
chorioretinal atrophy and
hyperpigmentation. Top right,
intraretinal fluid (white arrow), signs of
chorioretinal atrophy (green arrow)
and choroidal neovascular complex
(blue arrow) are present on the OCT
scan. Bottom left and right, early and
late phases of angiogram, respectively.
In the late phase a minimun leakage is
seen (white arrow).
Figure 3 The right eye of the same
patient of figure 1 after photodynamic
therapy. Top left, the fundus
photograph does not show
ophthalmoscopic signs of lesion activity.
Top right, an hyper-reflective lesion
related to the CNV complex identified
on fluorescein angiogram is identifiable
on OCT (white arrow), but no
intraretinal or subretinal fluid is seen.
Bottom left and right, early and late
phases of angiogram respectively,
show staining of the lesion but no
leakage.
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biomicroscopy and FA are needed to correctly establish a
diagnosis of CNV associated with pathological myopia.
In the current study, using OCT, we did not find significant
changes in CNV thickness after PDT (table 1). On one hand,
although we used foveal fixation and landmark functions to
achieve good image registration, it is possible that the
difficulty of precisely replicating the scan location could have
introduced errors in the interpretation of the changes in
lesion thickness over time.
On the other hand, PDT was reported to have a vaso-
occlusive mechanism that affects both the CNV and the
normal choroid.11 However, compared with other treatments
such as laser photocoagulation, CNV does not completely
resolve after PDT.12 Other authors,13 who reported histological
findings of surgically excised myopic choroidal neovascular
membrane after PDT, concluded that PDT induced only
temporary occlusion.
We did not find a significant correlation between BCVA
changes and pretreatment macular thickness or pretreatment
CNV thickness, which may indicate that pretreatment
macular thickness is not associated with the final success
of PDT. Sahni et al also reported that there was no statistically
significant association between the presence or absence of
intraretinal fluid and subretinal fluid and VA in patients with
ARMD who had undergone PDT.14
We reached the decision to retreat patients based on BCVA
and FA. The presence of fluorescein leakage from CNV was
the main criterion for retreating patients during follow up, as
reported previously.4 5 15 Nevertheless, we found that FA is
sometimes difficult to interpret.16–18 In the present study,
there was agreement on the presence of leakage between the
two observers in 84.39% of the angiograms with CNV
associated with pathological myopia. This agreement was
slightly less than the agreement we achieved when inter-
preting the angiograms of patients with ARMD.6 In our
experience, FA was inconclusive in a higher percentage of
eyes with CNV related to pathological myopia than in cases
with exudative AMD.6
In our study, OCT detected intraretinal or subretinal fluid
in 20 (30.3%) of the cases in which FA did not show clear
leakage. Recently, we found that in patients with ARMD,
OCT detected intraretinal or subretinal fluid in 14.2% of the
cases in which FA did not show clear leakage.6 We think that
in some cases of pathological myopia, leakage is even more
difficult to identify than in patients with AMD. CNV in
pathological myopia is often diagnosed in younger patients in
whom the RPE is involved with the neovascular complex, and
fluid is difficult to estimate with slit lamp biomicroscopy and
leakage is not always easily evaluated. Nevertheless, we do
not propose that the presence of intraretinal or subretinal
fluid in OCT indicates that treatment or re-treatment is
always required. The decision to treat or re-treat in each case
also must be based on slit lamp biomicroscopy, BCVA, and
the presence of leakage on FA. However, in accordance with
other authors, we propose that OCT may assist in therapeutic
decision making,6 14 19 especially when there are doubts based
on the results of other techniques.
In conclusion, OCT may be a good complementary imaging
technique in the decision making process regarding treat-
ment or re-treatment with PDT of CNV in pathological
myopia. This may be especially useful when FA is incon-
clusive15 or the general condition of the patient does not allow
frequent FA examinations.20 21
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